Amit Bhalla

In a report published Tuesday, Citigroup analyst Amit Bhalla reiterated a Buy rating on Edwards Lifesciences Corp. (NYSE: EW), but lowered the price target from $75.00 to $72.00. In the report, Citigroup noted, “On Monday (12/09/13), Edwards held its annual investor meeting in New York, NY where...

In a report published Friday, Citigroup analyst Amit Bhalla reiterated a Neutral rating on The Cooper Companies (NYSE: COO), but lowered the price target from $133.00 to $128.00. In the report, Citigroup noted, “COO reported a mixed overall quarter as channel inventory reductions (distributor...

In a report published Friday, Citigroup analyst Amit Bhalla reiterated a Buy rating on Agilent Technologies (NYSE: A), and raised the price target from $53.00 to $59.00. In the report, Citigroup noted, “This was a positive quarter for Agilent as questions over Electronic Measurement (EMG)...

In a report published Tuesday, Citigroup analyst Amit Bhalla reiterated a Neutral rating on Hologic (NASDAQ: HOLX), but lowered the price target from $24.00 to $22.00. In the report, Citigroup noted, “While HOLX beat the Street by $0.02 on the bottom-line, revenues came in light and F2014 guidance...

In a report published Wednesday, Citigroup analyst Amit Bhalla downgraded the rating on Hologic (NASDAQ: HOLX) from Buy to Neutral, but reiterated the $24.00 price target. In the report, Citigroup noted, “We are downgrading HOLX to Neutral (from Buy) as the stock price has significantly increased...

In a report published Wednesday, Citigroup analyst Amit Bhalla upgraded the rating on Edwards Lifesciences Corp. (NYSE: EW) from Neutral to Buy, and raised the price target from $75.00 to $86.00. In the report, Citigroup noted, “We are upgrading EW to Buy (from a Neutral) and are increasing our...

Citi analyst Amit Bhalla reiterated a Buy rating for Alimera Sciences (NASDAQ:ALIM) today. Alimera is a biopharmacist specializing in prescription ophthalmic pharmaceuticals. ALIM is down 37% since its IPO on April 23rd, 2010, compared to -14% for the S&P. Citi thinks that this represents an...

Analyst Amit Bhalla at Citigroup (NYSE: C)has downgraded Cardionet, Inc. (NASDAQ: BEAT) from Hold to Sell rating. Citigroup recently hosted the company’s management at its annual healthcare conference. Although the company appears to be progressing ahead on schedule on its cost saving initiatives...

Citi Investment Research & Analysis analyst Amit Bhalla gave shares of medical device company CareFusion Corporation (NYSE: CFN) a rating of Hold, with a target price of $29 per share. CareFusion Corporation said that it is capable of meeting excess demand and that the company is on track to...